T. Rowe Price Associates’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

T. Rowe Price Associates’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,500	Closed	-$67K	–	3044
2021 Q2	$67K	Hold	10,500	–	–	﹤0.01%	2880
2021 Q1	$66K	Buy	+10,500	New	+$75K	﹤0.01%	2811
2017 Q3	–	Sell	-5,547	Closed	-$54K	–	2614
2017 Q2	$54K	Buy	5,547 +5	+0.1%	+$102	﹤0.01%	2524
2017 Q1	$134K	Hold	5,542	–	–	﹤0.01%	2459
2016 Q4	$178K	Hold	5,542	–	–	﹤0.01%	2404
2016 Q3	$277K	Hold	5,542	–	–	﹤0.01%	2251
2016 Q2	$235K	Buy	5,542 +1,500	+37%	+$81.7K	﹤0.01%	2265
2016 Q1	$266K	Hold	4,042	–	–	﹤0.01%	2203
2015 Q4	$251K	Sell	4,042 -2,745	-40%	-$193K	﹤0.01%	2220
2015 Q3	$454K	Buy	6,787 +1,284	+23%	+$105K	﹤0.01%	1998
2015 Q2	$535K	Buy	5,503 +1,881	+52%	+$179K	﹤0.01%	1969
2015 Q1	$339K	Sell	3,622 -1,564	-30%	-$133K	﹤0.01%	2136
2014 Q4	$461K	Buy	5,186 +1,920	+59%	+$140K	﹤0.01%	1990
2014 Q3	$226K	Hold	3,266	–	–	﹤0.01%	2280
2014 Q2	$187K	Buy	3,266 +1,359	+71%	+$69K	﹤0.01%	2368
2014 Q1	$76K	Hold	1,907	–	–	﹤0.01%	2453
2013 Q4	$80K	Sell	1,907 -169,309	-99%	-$4.91M	﹤0.01%	2423
2013 Q3	$5.12M	Buy	+171,216	New	+$5.99M	﹤0.01%	1420

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

T. Rowe Price Associates's MACK Position: Q3 2021 in Review

T. Rowe Price Associates sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2021, closing a stake of 10,500 shares — an estimated $67K sold.

T. Rowe Price Associates first reported a position in MACK in Q3 2013 and held it in 18 quarters. The position peaked at $5.12M in Q3 2013. 39 funds tracked by Wall St. Rank hold MACK as of Q3 2021.

T. Rowe Price Associates reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
T. Rowe Price Associates sold 10,500 Merrimack Pharmaceuticals, Inc. shares in Q3 2021, an estimated $67K.
T. Rowe Price Associates first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 18 quarters.
T. Rowe Price Associates's Merrimack Pharmaceuticals, Inc. position peaked at $5.12M in Q3 2013.
39 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2021.

Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.